



# 2019 annual results


4 March 2020

# Disclaimer

---

This document may contain information related to the Group's outlook. Such outlook is based on data, assumptions and estimates that the Group regarded as reasonable at the date of this document. Those data and assumptions may change or be adjusted as a result of uncertainties relating particularly to the economic, financial, competitive, regulatory or tax environment or as a result of other factors of which the Group was not aware on the date of this document. Moreover, the materialization of certain risks described in chapter 2 "Risk factors & risk control, insurance policy, and vigilance plan" of the Registration Document may have an impact on the Group's activities, financial position, results or outlook and therefore lead to a difference between the actual figures and those given or implied by the outlook presented in this document. Reaching the outlook also implies success of the Group's strategy.

As a result, the Group makes no representation and gives no warranty regarding the attainment of any outlook set out in this document.



## 2019 business highlights

Operational performance

Strategy and business resilience

A responsible business

2020 outlook

# 2019: Another year of solid growth and strong results for Elis



## Solid financial performance

- Revenue up +4.7%
- Solid +3.3% organic growth
- EBITDA margin remains strong at 31.5%\*
- Headline net result up +16%\*
- Free cash flow of €186mn, up +21%\*



## Strong operational improvements

- Good commercial momentum
- Positive outcome of price negotiations
- Client retention rate improvement across the board
- Further productivity gains in all geographies



## Integration of Berendsen and extra capex plan are now finished


- Catch-up capex program fully implemented
- Improvement of operational KPIs in the UK, paving the way for future profitability increase

\* Frozen GAAP (i.e. excluding IFRS 16 impact)


Taking into account the impact of IFRS 16, EBITDA margin is up +210bps vs 2018, Headline net result is up +14% vs 2018 and Free cash flow is up +61% vs 2018

# Elis offers a well-balanced business mix, client base and geographical footprint


2019 revenue by activity



2019 revenue by end-market




2019 revenue by geography



# Strong organic growth driven by price effect and good commercial momentum


FY 2019 organic growth vs FY 2018 pro forma organic growth



<sup>1</sup> Excluding the Clinical Solutions activity for 2019 and 2018 (UK & Ireland only)


# Stable EBITDA margin despite high inflation and negative product mix effect in some geographies

EBITDA margin (2019 vs 2018, excluding IFRS 16 impact)



<sup>1</sup> Excluding the Clinical Solutions activity for 2019 and 2018 (UK & Ireland only)  
 EBITDA margin numbers including IFRS 16 are disclosed page 21 of this presentation

# Elis confirms its ability to increase prices in a context of high cost inflation



## Elis market position led to positive pricing negotiations all along the year

- **Strong market share** and good **commercial relationships** with customers have been key factors for **successful pricing negotiations**
- **Positive outcome** in most countries, with the exception of Germany




# France: Good overall performance leading to further margin improvement

## Good performance in 2019

- Supportive underlying trends in all end-markets
- Good commercial dynamism and improvement of client retention
- Positive pricing effect
- Further productivity gains
- Very limited impact from the December strikes

## Steady EBIT margin improvement (excl. IFRS 16)

- France has steadily improved its EBIT margin over the last decade, leveraging its positioning and know-how



Restated from the impact of the change in depreciation period (as disclosed on page 9 of the IPO Prospectus).

**+3.2%** organic growth

**35.7%** EBITDA margin (+70bps) excluding IFRS 16

**38.0%** EBITDA margin including IFRS 16



# Central Europe: Strong performance in the Netherlands and Poland but Germany and Switzerland remain subdued

## The Netherlands and Poland

- **Very good performance** with strong organic growth numbers, driven by a dynamic Workwear segment in both countries and significant new outsourcing in Poland

## Switzerland

- **Highly cash generative country** but little traction in the market

## Germany

- +4% organic growth in **Workwear**
- Negative mix effect on margin due to our acquisitions in **Healthcare**, in the context of our consolidation strategy
- Prices still too low in **Hospitality** due to fragmented market
- **Low unemployment rate** in the country leading to significant **wage inflation that was difficult to offset**

## Others

- Belux, Czech, Slovakia and Hungary are good performers overall with some good performances in Workwear
- Up to **double-digit organic growth** and **EBITDA margin above 35%** in some countries

**+2.8%** organic growth


**29.6%** EBITDA margin (-100bps) excluding IFRS 16

**31.6%** EBITDA margin including IFRS 16

# Scandinavia & Eastern Europe: Solid organic growth, mostly driven by the Flat linen segment

## Sweden, Denmark and Finland:


➤ **Stronger growth in Flat linen** (especially in Hospitality) than in Workwear, generating a **negative mix effect on margin**



Segment Mix effect


## Other countries:

➤ **Mid-single to strong double-digit organic** revenue growth, as well as margin improvement, but **negative mix effect at region level**, as margin in those countries is still lower than the region's



Country Mix effect

**+3.7%** organic growth  
**36.6%** EBITDA margin (-80bps) excluding IFRS 16  
**38.7%** EBITDA margin including IFRS 16




# UK: Operational improvements continue but pricing improvement in Hospitality could not entirely offset contract losses in Workwear

## Improvement of retention in Workwear

- **Our customer-focused approach** is bearing fruit
- **Loss of a material retail** contract due to the closing of one of this client's activity
- **Doubling of the number of Account Managers (i.e. + 16 FTEs)** by the end of Q1 2020 to boost growth in Workwear


### Sequential reduction in churn rate



## Price increase in Hospitality

- **Quality of service** restored by applying Elis standards
- Some client losses due to **pricing discipline** as part of our margin-focused approach

### Good price increase momentum



-1.2% organic growth  
 25.8% EBITDA margin (-60bps) excluding IFRS 16  
 28.6% EBITDA margin including IFRS 16



# Southern Europe: Successful pricing negotiations and good momentum in Workwear



➤ **Successful pricing negotiations in Spain** in an unusually high wage inflation environment: +22% increase in minimum wage in Spain (with a c. 8% increase in Elis labor costs in 2019)



➤ Elis leveraged its **strong market position** to clinch good negotiation outcomes



➤ **Marked outsourcing trend in Workwear in both Spain and Portugal**, with double-digit organic growth rates for the segment in both countries

**+7.4%** organic growth


**27.0%** EBITDA margin (+60bps) excluding IFRS 16

**28.8%** EBITDA margin including IFRS 16



# Latin America: Very good commercial dynamic and further growth potential identified

- ▶ **Commercial momentum remains very good** in Brazil with strong growth in **outsourcing** and low inflation in 2019
- ▶ **Political and economic environment somewhat stabilized** in Brazil after several years of volatility
- ▶ **Brazil reached 30% EBITDA margin in 2019** (compared to 20% when Elis entered the country in 2014)
- ▶ **Colombia** remains a small contributor but is **well-oriented**
- ▶ **Chile suffered from violent protests** since October but remains a very small contributor to the region




**+7.1%** organic growth

**28.8%** EBITDA margin (+190bps) excluding IFRS 16

**30.4%** EBITDA margin including IFRS 16

# Elis continued its targeted acquisition strategy with 6 bolt-on acquisitions closed in 2019 and 1 deal closed in 2020 YTD



FY 2019 M&A impact: +1.8%

FY 2020 embedded M&A impact: +0.3%

# Elis' capex plan for Berendsen has been rolled-out according to budget and phasing, and is now completed



**c. €330mn**

invested over 2017-2019



**7** new plants

o/w **3** in UK




**10** upgraded plants

o/w **4** in UK



**+ c. €75mn** spent  
on maintenance and  
efficiency



Berendsen countries' asset base quality is now fully in line with Elis' standards



# Elis can now leverage its international platform to sign cross-border agreements

## New agreement with

### Previous situation

- **3-year** deal
- **6** countries
- **3,000** wearers
- Desire to standardise garments across countries

### New situation

- **5-year deal**
- **11** countries
- **10,000** wearers
- Implementation to begin Q3 2020

## New long-term agreement with novo nordisk®

- **Largest insulin producer in the world**, based in Copenhagen
- **16** production locations worldwide
- New **long-term agreement** (Umbrella) for cleanroom articles in Brazil, Denmark, France & Russia (textiles, goggles, mops, wipes, etc...)

## Signature of a new contract with SAFRAN

- **5** countries  
(France, Belgium, Poland, Germany, Czech Republic)
- **63** sites
- **225,000** garments and **21,000** wearers

## Other pan European contracts signed since the Berendsen acquisition



Scandic

Marriott



valspar



# Notes

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---



2019 business highlights

**Operational performance**

Strategy and business resilience

A responsible business

2020 outlook

# Introductory comments (1/2)

## 2018 & 2019 figures exclude Clinical Solutions

- In H1 2018 the Group initiated the sale process for its Clinical Solutions (operating only in the United Kingdom) and sold the activity in two parts in August and October 2019.
- The figures presented in this presentation exclude the entire activity of Clinical Solutions in 2019 and 2018, which has been reclassified as discontinuing

## IFRS 16 (effective 1<sup>st</sup> January 2019)

- Principle: Lease expense is now considered as amortization and financial expense (previously above EBITDA)
- The application of IFRS 16 standards has an impact on several Group aggregates, as shown in the table below:

	(in €mn)	2019
	<b>EBITDA</b>	<b>70.3</b>
Depreciation and amortization including portion of grants transferred to income		(66.6)
	<b>EBIT</b>	<b>3.7</b>
	<b>Financial result</b>	<b>(9.6)</b>
	<b>Net result</b>	<b>(4.2)</b>

- Other impacts:
  - Cash impact: Lease payments are now included in financing activities and no longer in free cash flow (€61.4mn reclassification)
  - Covenant: No impact (frozen GAAP)

## Introductory comments (2/2)

### IFRS 16 impact on EBITDA margin

Zone	Excl. IFRS 16		var.	Incl. IFRS 16	IFRS 16 impact
	2019 EBITDA %	2018 EBITDA %		2019 EBITDA %	
France	35.7%	35.0%	+70bps	38.0%	+230bps
Central Europe	29.6%	30.6%	-100bps	31.6%	+200bps
Scandinavia & Eastern Europe	36.6%	37.4%	-80bps	38.7%	+210bps
UK & Ireland	25.8%	26.4%	-60bps	28.6%	+280bps
Southern Europe	27.0%	26.4%	+60bps	28.8%	+180bps
Latin America	28.8%	26.9%	+190bps	30.4%	+160bps
Group	31.5%	31.5%	=	33.6%	+210bps

# Headline net result up +16% excluding IFRS 16

(In €mn)	2019	Of which IFRS 16	2018	% change
Revenue	3,281.8	-	3,133.3	+4.7%
EBITDA	1,103.0	+70.3	985.6	+11.9%
As a % of revenue	33.6%	+210bps	31.5%	+210bps
EBIT	454.9	+3.7	426.4	+6.7%
As a % of revenue	13.9%	+10bps	13.6%	+30bps
Current operating income	442.1	-	407.5	+8.5%
Amortization of intangible assets recognized in a business combination	(88.3)	-	(112.5)	
Non current operating income and expenses	(18.5)	-	(49.8)	
Operating income	335.3	-	245.2	+36.7%
Financial result	(150.0)	(9.6)	(110.5)	
Tax	(47.6)	+1.7	(51.7)	
Net result from continuing operations	137.7	(4.2)	83.0	+65.9%
Net result	141.9	(4.2)	81.8	+73.4%
Headline net result	256.1	(4.2)	224.3	+14.2%
Headline net result excluding IFRS 16	260.3	-	224.3	+16.0%

➤ **Lower PPA amortization in 2019** due to the end of the amortization of the 2007 **Eurazeo takeover PPA**, partially offset by the beginning of the **Lavebras and Berendsen PPA amortization**

➤ Includes acquisitions and divestments transaction costs

➤ Lower **restructuring costs in 2019** as most of Berendsen headcount adjustments were made **in 2017 and 2018**

➤ Financial result made up of:

- Financial debt interests for c. €60mn
- One-off items primarily linked to the 2019 refinancing for €45mn
- Amortization of issuing costs of previous loans for c. €12mn
- Notional interests of OCEANE for €9mn
- c. €10mn of interest expenses on leases due to IFRS 16

# 2019 headline net result calculation

(In €mn)	2019	2018
Net result	137.7	83.0
Amortization of intangible assets recognized in a business combination*	70.7	86.6
IFRS 2 expense*	10.6	15.6
Accelerated amortization of loans issuing costs *	12.2	2.6
Breakup costs (refinancing)*	4.5	-
Unwinding of swaps*	12.9	-
<b>Non current operating income and expenses:</b>	<b>7.5</b>	<b>36.4</b>
<i>o/w litigation provisions reversal</i>	<i>(11.6)</i>	<i>(0.6)</i>
<i>o/w acquisition-related costs*</i>	<i>6.6</i>	<i>22.3</i>
<i>o/w restructuring costs*</i>	<i>6.5</i>	<i>22.2</i>
<i>o/w other*</i>	<i>6.0</i>	<i>(7.5)</i>
<b>Headline net result</b>	<b>256.1</b>	<b>224.3</b>
IFRS 16 impact on 2019 net result	(4.2)	-
<b>Headline net result excluding IFRS 16</b>	<b>260.3</b>	<b>224.3</b>

\* Net of tax effect

## 2019 financial charges (cash & non-cash)

(In €mn)	P&L	(In €mn)	Cash-flow
<b>Financial debt interests</b>	<b>(60.3)</b>	<b>Financial debt interests (cash)</b>	<b>(60.3)</b>
Break-up fees	(6.0)	Break-up fees	(6.0)
Interest paid (lease debt)	(9.9)	Interest paid (lease debt)	(9.9)
Interest rates swaps	(3.9)	Interest rates swaps	(4.6)
Recurring fees	(4.9)	Recurring fees	(6.7)
Notional interests (OCEANE)	(8.9)	Unwinding of swaps	(24.4)
Amortization of issuing costs	(30.8)	Other	1.1
Fair value (derivatives)	(20.8)		
Other	(4.5)		
<b>P&amp;L charge</b>	<b>(149.9)</b>	<b>Cash outflow</b>	<b>(110.7)</b>

- Average cost of debt c. 1.5%



# Significantly stronger free cash-flow generation in 2019

	(In €mn)	2019	Of which IFRS 16	2018
<b>EBITDA</b>		<b>1,103.0</b>	<b>+70.3</b>	<b>985.6</b>
Exceptional items and variance of provisions		(24.4)		(35.5)
Acquisition and divestment transaction costs		(10.2)		(4.4)
Other		(0.6)		-
<b>Cash-flow before net financial costs and tax</b>		<b>1,067.8</b>		<b>945.7</b>
Net capex (linen + industrial)		(660.3)		(644.3)
Change in working capital		26.9		(15.8)
Net interests paid		(110.7)	(8.9)	(55.2)
Income tax paid		(76.2)		(76.7)
<b>Free cash-flow</b>		<b>247.5</b>	<b>61.4</b>	<b>153.7</b>
Lease liabilities payments - principal		(73.3)	(61.4)	(3.0)
Acquisitions of subsidiaries, net of cash acquired		(83.2)		(62.2)
Change arising from subsidiaries (gain or loss of control)		(15.1)		(12.7)
Other flows related to financing operations		(20.0)		(26.4)
Proceeds from disposal of subsidiaries, net of cash transferred		30.0		1.0
Dividends paid		(81.2)		(81.1)
Equity increase, treasury shares, lease reclassification from financial to liabilities		29.0	22.9	1.5
Other		(48.0)		(41.8)
<b>Net debt variance</b>		<b>(14.4)</b>	<b>22.9</b>	<b>(71.1)</b>

► **Capex to sales ratio of 20.1%**  
(taking into account Clinical Solutions revenue )

► **Improved working capital** due to very good cash-in from clients at year-end and to some extent to a c. €15mn one-off related to CICE change in regulation

► Impact of **debt refinancing**: c. €30mn of non recurring items of which c. €24mn to unwinding of swaps

# 2019 refinancing has lowered average cost of debt and further extended maturities

## A well-diversified financing

As of 31 December 2019


<b>BOND (issued 10/2019)</b> €500mn	Coupon 1.0% Maturity 2025
<b>BOND (issued 10/2019)</b> €350mn	Coupon 1.625% Maturity 2028
<b>BOND (issued 04/2019)</b> €500mn	Coupon 1.75% Maturity 2024
<b>USPP (signed 04/2019)</b> €335mn	Coupon 2.70% Maturity 2029
<b>BOND</b> €650mn	Coupon 1.875% Maturity 2023
<b>BOND</b> €350mn	Coupon 2.875% Maturity 2026
<b>CONVERTIBLE BOND</b> €365mn	Coupon 0% Maturity 2023
<b>COMMERCIAL PAPERS</b> €382mn	N/A
<b>SCHULDSCHEIN</b> €75mn	Maturity 2020 – 2024
<b>REVOLVING</b> Undrawn €900mn	Maturity 2022 (€500mn) Maturity 2023 (€400mn)

### Latest ratings:

- Moody's: **Ba2, positive**
- S&P: **BB+, stable**
- DBRS: **BBB low, stable**

**Net debt/EBITDA ratio of 3.2x** as of 31/12/2019

## Extended maturities



## Our debt policy

- A well-diversified debt structure policy
- Balance sheet efficiency
- Continuous search for refinancing opportunities

A stack of white, folded linens, likely hotel bedding, is shown on the left side of the slide. The linens are neatly folded and stacked, with the top one showing a striped pattern.

# Key financial takeaways

1

Good topline momentum, underpinning Elis' ability to negotiate price increases in a high-inflation environment

2

Resilient EBITDA margin: 33.6%  
(stable at 31.5% excluding IFRS 16)

3

Headline net result of €256mn  
(up +16% at €260mn excluding IFRS 16)

4

Improvement of free cash-flow generation at €247mn  
(up +21% at €186mn excluding IFRS 16)

# Notes

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---



2019 business highlights

Operational performance


**Strategy and business resilience**

A responsible business

2020 outlook

# Elis has become an international Group offering a highly-diversified and well-balanced profile

Elis revenue breakdown over the last 20 years



Berendsen


- High exposure to France, especially to the Hospitality market
- Fairly concentrated client base



- Diversified **geographical mix**: Balanced presence across Western Europe, Scandinavia and Latin America
- Diversified **client base**: Top 10 clients < 10% of revenue
- Diversified **end-markets**: Industry (c. 29%), Hospitality (27%), Healthcare (26%) and Trade and Services (18%)




# The Group has proven business resilience over the years



- Over the last **19** years, Group revenue has posted **continuous organic growth** and **EBITDA margin** has evolved within a **narrow range**
- Our business offers a **silver lining**: When there is lower revenue growth, **linen capex is lower**, resulting in **higher cash generation**

\* Excluding IFRS 16 (33.6% including IFRS 16)

# Value creation from cross-selling initiatives



## The Service Agent

- More than a simple driver, he is the **frontline touchpoint** with clients
- Develop a **close relationship with its clients**
- **Incentivized to cross-sell**



## Multiservice strategy


- **Multiservice plants** to deliver all the products with the **same truck**
- Revenue from additional products signed with existing clients **flows down to the margin as most costs are already in place**



# Turning drivers into Service Agents to improve retention: The UK example

1

Elis' tribe structure introduced



2

Service/Sales Training delivered



3

Customer-focused objective with incentives

- › Retention of portfolio
- › New business
- › Customer relationship
- › Proximity

## The Elis Service Agent plays a key role in customer retention improvement

- › **Proximity with the customers** means higher quality of service
- › **48 out of the 124** workwear drivers already promoted to Service Agents, with larger responsibilities and incentive options
- › **Positive** customer feedback
- › **Sales wins** starting to come through

# Leveraging our network density to address small clients: The Brazilian example



## Objective:


Target the small accounts in Brazil



## Principles:

Focus on the 11 main Brazilian cities

- › 37 million people targeted
- › Around 420k potential customers
- › Initial portfolio of 22 items (flat linen, RFID)



2017

### Phase 1

- › Pilot in São Paulo
- › 1 sales person
- › Beauty & wellness (spas, gyms, hairdressers...)

€ Turnover: €89k

2018

### Phase 1 (continued)

- › Reinforce São Paulo
- › Sales Team: 4 FTE
- › Beauty & wellness

€ Turnover: €345k

2019

### Phase 2

- › São Paulo and Curitiba
- › Sales Team: 11 FTE
- › Beauty/wellness, restaurants
- › Av. monthly sales/FTE: €730


€ Turnover: €1.1mn

# Strong Workwear outsourcing potential in many countries

Brazil and Spain offer very strong growth prospects in their domestic Workwear market




**Brazil**



- 60% of the existing market is still operated by internal laundries (mainly in Healthcare)
- Workwear market is composed mainly of uniforms for Industry and Healthcare

**Spain**



- 2019: Significant contracts signed in Pharma, Food processing and Retail
- c. 10 FTEs to be hired to develop the market

➤ Other countries should see significant growth of their outsourced Workwear market in the coming years: Poland, Baltics, Czech Republic, etc...

# Traceability solution becomes a differentiating factor in our industry

## Traceability is valuable to our clients

- Using **RFID technology**, *Elis connect* portal provides clients with **real-time information** on their linen inventory to **optimize their linen orders** and **avoid excess inventory**
- *Elis connect* tools let the client know when the level of a hygiene product is running low, **enabling replacement of the product before it runs out**

This leads to higher **client retention**



**ACCESS**  
Proof of passage



Improve **trust**

**FOCUS**  
Proof of service



Offer **visibility**

**VISION**  
Advanced solutions



**Empower**

# Our target: Raise all the countries to the level of the Group's top performers

EBITDA margin below 25%	Revenue (in €mn)	EBITDA margin 25%-30%	Revenue (in €mn)	EBITDA margin 30%-35%	Revenue (in €mn)	EBITDA margin >35%	Revenue (in €mn)
Chile	25	Germany / Austria	395	Portugal	60	France	1,065
Colombia	15	UK	345	Brazil	225	Sweden	215
Russia	5	Spain	210	Baltics	15	Denmark	195
		Switzerland	100	Finland	15	The Netherlands	130
		Ireland	50			Norway	60
		Belux	40			Poland	50
		Italy	30			Czech Republic / Slovakia / Hungary	15

Note:  
 2019 revenue actual figures (rounded)  
 UK excluding Clinical Solutions activity  
 EBITDA margin including IFRS16 impact

Market share gains, transfer of best practices and footprint enhancement are the main drivers for margin improvement





2019 business highlights

Operational performance

Strategy and business resilience

**A responsible business**

2020 outlook

# Our impact on society: Our commitments



Taking responsibility  
for our **impact on  
society** through  
responsible products  
and services

## Responsible supply chain 2025

**95%** of the preferred suppliers  
covered by CSR assessment

## Ethical business 2025

**100%** people in sensitive positions  
trained in anti-bribery and corruption

## Educational support 2025

**Triple** the budget available  
for the Elis Foundation

# Our environmental footprint: Our commitments









Continuously reducing  
our business'  
**environmental footprint**

## Reduce, re-use and recycle 2025

**80%** textiles recycled

**Identification of new ways of recycling:** Acoustic isolation, recycling in the furniture industry, re-use of textiles in carbon fibre for industry

## 2010-2025 consumption targets ahead of schedule

- >  **Water: -50%** 2019 achieved: **-41%** Remaining
- >  **Chemicals: -37%** 2019 achieved: **-26%** Remaining
- >  **Gas: -35%** 2019 achieved: **-23%** Remaining
- >  **Fuel:** Increase the number of **eco-friendly vehicles** 
- >  **CO2 emissions: -20%** 2019 achieved: **-15%** Remaining



# Our employees' well-being: Our commitments



Empowering  
**employees'**  
**well-being** and **growth**

## Safety 2025

**50%** decrease in lost time from accidents  
(base year: 2019)

## Personal and professional growth 2025

- › **Chevrons** deployed in all operational Elis countries
- › Increase retention of key personnel through **talent development**

## Diversity 2025

**40%** of women in permanent management positions



2019 business highlights

Operational performance

Strategy and business resilience

A responsible business

**2020 outlook**

# 2020 outlook

---

1

Organic growth of c. +3%

2

EBITDA margin up c. +20bps

3

Group free cash-flow of c. €320mn, compared to €247mn in 2019


















This outlook does not take into account:

- The potential future impacts related to the Covid-19 health crisis. As of today, only limited impact has been noted in Hospitality in France (Paris & South East)
- Any change in FX

This outlook has been prepared in a manner comparable to the historical financial information, and in line with the Group's accounting methods.

# Elis should prove its resilience in a context of a spreading Coronavirus disease

Revenue: Some potential impact, which has not been quantified to date, mainly in Hospitality

2019 revenue	Main revenue contributors	Potential impact on 2020 revenue	Comment
 <p>c. €940mn 29% of total</p>	     	➤ Very limited	Most workwear <b>contracts are on a per-wearer basis</b> . A contained <b>slowdown in activity will not lead to significant headcount reductions at our clients'</b>
 <p>c. €890mn 27% of total</p>	  	➤ Potentially material	Mostly <b>volume-based contracts</b> . A global travel slowdown would have an impact on our revenue. In 2009 (H1N1 crisis), Elis' Hospitality revenue was down 2%
 <p>c. €870mn 26% of total</p>	  	➤ Nil to positive	Potentially <b>more hospitalizations and higher demand for washroom products</b> such as gel hand sanitizers (same in all end-markets)
 <p>c. €590mn 18% of total</p>		➤ Limited	Mostly fixed-fee contracts so <b>no major impact expected</b>



Industry



Hospitality



Healthcare



Trade & Services



# Elis should prove its resilience in a context of a spreading Coronavirus disease

---

## Profitability: No major impact expected thanks to cost-base flexibility

- Thanks to **labor contract agreements**, Elis has the capacity to **adjust its employees' working hours** when activity goes down, hence making these **fixed costs somewhat variable**
- Other main production costs (temp workers, water, natural gas, electricity) are variable by nature
- **No supply chain impact**: Sourcing is local for chemical products, water, gas and is largely diversified for linen with virtually no exposure to China or South Korea

## Cash generation: Limited impact expected

- In **case of significant activity downturn, our linen investments would decrease** accordingly as lower consumption of linen by our clients (lower occupancy rates in hotels, reduced number of shifts in plants using uniforms, etc...) means lower rotation / need for replacement for Elis
- Industrial capex in connection with additional capacity needs can be postponed if activity drops significantly

## Conclusion:

A good 2019 year, paving the way for further improvements in 2020

---

- **Resilient EBITDA margin in 2019**, thanks to our ability to pass on inflation, improve client retention and leverage on our commercial dynamism
- **End of extra capex plan** for Berendsen in line with budget and phasing schedule
- **Improved cash flow** generation

With capex back to normative level and optimized debt structure, **Elis offers long-term and solid free cash-flow generation perspective**





**Nicolas Buron**

Investor Relations Director

Tel: +33 1 75 49 98 30

Mob: +33 6 83 77 66 74

Email: nicolas.buron@elis.com

**Audrey Bourgeois**

Investor Relations

Tel: +33 1 75 49 96 25

Mob: +33 6 99 47 80 56

Email: audrey.bourgeois@elis.com

**ELIS SA**

5, boulevard Louis Loucheur

92210 Saint-Cloud

France

<https://fr.elis.com/en>